×

Cambridge Healthtech Institute (CHI) is closely monitoring the continuing developments on COVID-19. Currently, there is no plan to cancel or postpone this event. CHI is tracking all travel restrictions issued by the Public Health England, as well as information and guidance from the U.S. Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO).

New - No Questions Asked Cancelation Policy
10 - 11 MARCH Preclinical and Translational Immuno-Oncology
10 - 11 MARCH Immunomodulatory Approaches
10 - 11 MARCH CARs, TILs, TCRs
11 - 12 MARCH Biomarkers for Immuno-Oncology
11 - 12 MARCH Combination Immunotherapy
11 - 12 MARCH Bispecific Antibody Design and Applications
250+
I-O
Thought Leaders
100+
Scientific Presentations
9
Days of Programming
61%
Industry
Delegates


2020 Plenary Keynote Speakers

Stanley Riddell, MD, Scientific Director, Clinical Research, Fred Hutchinson Cancer Research Center; Professor, University of Washington School of Medicine

Kandeepan Ganeshalingam

Kandeepan Ganeshalingam, MD, Executive Director,Therapeutic Area Head Oncology, European Clinical Development Global Clinical Development, MRL, Merck Sharp & Dohme (MSD)


Additional 2020 Featured Speakers

Renier Brentjens, MD, PhD, Director, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center; Professor, Pharmacology, Weill Cornell Graduate School of Medical Sciences

George Coukos, Full Professor and Director, Oncology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL); Director, Lausanne Branch, Ludwig Institute of Cancer Research Chief, Service of Immuno-Oncology, CHUV

Lindy Durrant, PhD, Professor of Cancer immunotherapy, University of Nottingham; CSO, Scancell Ltd

Gordon J. Freeman, PhD, Professor of Medicine, Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School

Maria Karasarides, PhD, Executive Director, ImmunoOncology, Regeneron Pharmaceuticals

Roland Kontermann, PhD, Professor, Biomedical Engineering, Institute of Cell Biology and Immunology, University of Stuttgart

Andrew Sewell, PhD, Distinguished Research Professor and Wellcome Trust Senior Investigator, Infection & Immunity, Cardiff University School of Medicine

Christophe-Le-Tourneau

Christophe Le Tourneau, MD, PhD, Senior Medical Oncologist, Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France

Jeanette Leusen, PhD, Associate Professor and Head Immunotherapy Group, Translational Immunology, University Medical Centre Utrecht

Wouter Scheper, PhD, Senior Postdoc, Molecular Oncology and Immunology, Netherlands Cancer Institute

Karoline Schjetne, PhD, Vice President Scientific Affairs, Vaccibody

Hans van der Vliet, MD, PhD, CSO, LAVA Therapeutics; Medical Oncologist, Amsterdam UMC

 

VIEW ADDITIONAL ATTENDEE QUOTES

 

Download Brochure
Download Event-at-a-Glance
Attendee Breakdown
Final Days 
to Register


ABOUT THE EVENT

Cambridge Healthtech Institute’s Fifth Annual Immuno-Oncology Summit Europe returns to the heart of London’s Canary Wharf for four days of cutting edge science and discussion. Through six conference tracks, delegates will hear from the research teams at the forefront of the rapidly developing field of cancer biotherapeutics.